Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp66 | Bone development/growth and fracture repair | ECTS2013

The P2Y2 receptor restrains BMD during development

Syberg Susanne , Ellegaard Maria , Schwarz Peter , Jorgensen Niklas Rye

The P2Y2 receptor is a G-protein-coupled receptor and the natural ligands (ATP/UTP) strongly inhibit mineralized bone nodule formation by osteoblasts in vitro. We have earlier shown that overexpression of the P2Y2 receptor in vivo resulted in decreased bone mineral density (BMD), partially due to increased bone resorption, but also decreased formation (detected by serum bone markers and bone histomorphometry).This ...

ba0001pp237 | Cell biology: osteocytes | ECTS2013

Nucleotide and mechanically induced ATP release pathways in osteocytes

Kringelbach Tina M , Novak Ivana , Schwarz Peter , Jorgensen Niklas Rye

Background: We have previously shown that MLO-Y4 osteocytes express a number of P2 receptors, respond to a broad range of nucleotides (e.g. UTP) by increasing intracellular calcium concentration and release ATP upon both mechanical and UTP stimulation. The aim of this study therefore is to investigate how the osteocytes release ATP and whether there is a difference in release pathway depending on the type of stimulus.Methods: ATP release was investigated...

ba0001pp285 | Muscle, physical activity and bone | ECTS2013

Prolonged botulinum toxin type A-induced muscle paralysis results in loss of bone mineral density and bone strength in young female rats

Ellegaard Maria , Syberg Susanne , Jorgensen Niklas Rye , Schwarz Peter

Transient paralysis by a single injection of botulinum toxin type A (Botox) in rodents has been shown to cause local bone loss of the affected leg. The animals regain function of the leg within 3–4 weeks and bone loss slowly recovers. The duration of the paralysis is dose-dependent. However, higher doses of Botox cause weight loss and decreased activity level.Aim of study was to investigate whether repeated injections of low-dose Botox could induce ...

ba0003oc4.6 | Genetics of bone disease | ECTS2014

Gout is associated with an excess risk of osteoporotic fracture: findings from a Danish registry

Dennison Elaine , Rubin Katrine H , Harvey Nick , Walker-Bone Karen E , Schwarz Peter , Cooper Cyrus , Abrahamsen Bo

Objective: Although metabolic syndrome is common in gout patients, recent reports that bone mineral density may actually be reduced (and falls common) in this group have led researchers to hypothesise that osteoporotic fracture may be more common in subjects with gout than in healthy controls. We tested this hypothesis in a national Danish registry.Material and Methods: We identified subjects as new users of allopurinol, a proxy for gout, for the years 1...

ba0003pp309 | Osteoporosis: treatment | ECTS2014

Treatment of severe vertebral osteoporosis with teriparatide or 1--84-PTH: results from a Danish Database Initiative

Hyldstrup Lars , Langdahl Bente L , Eiken Pia , Hermann Pernille , Schwarz Peter , Moeller Marianne Kleis , Bennedbaek Finn , Madsen Ole Rintek , Abrahamsen Bo , Stilgren Lis , Smitz Anita , Pelch Randi , Brockstedt Helle , Jarlov Anne , Morch Marianne , Sorensen Henrik Ancher , Mortensen Lene , Andreasen Per Nygaard , Hoeck Hans Christian , Jensen Jens-Erik Beck

A Danish database initiative was established in 2003 with the purpose of evaluating patients treated with teriparatide. After the introduction in 2006 of 1–84-PTH, these patients were also included. A total of 1494 patients from 19 centers were reported to the database, until closure in 2011. The reported patients correspond to a third of all patients in Denmark receiving anabolic treatment during this time period. With regard to age and sex the reported patients do not d...